TCM
ACRS icon

TCG Crossover Management’s Aclaris Therapeutics ACRS Stock Holding History

TCG Crossover Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-529,839
Closed -$5.49M – 27
2023
Q2 		$5.49M Hold
529,839
– – 0.9% 20
2023
Q1 		$4.29M Sell
529,839
-615,100
-54% -$7.81M 0.84% 19
2022
Q4 		$18M Hold
1,144,939
– – 3.18% 12
2022
Q3 		$18M Hold
1,144,939
– – 5.41% 8
2022
Q2 		$16M Hold
1,144,939
– – 6.79% 6
2022
Q1 		$19.7M Buy
1,144,939
+62,726
+6% +$856K 7.92% 4
2021
Q4 		$15.7M Buy
+1,082,213
New +$16.4M 7.37% 6

Other funds holding ACRS

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TCG Crossover Management's ACRS Position: Q3 2023 in Review

TCG Crossover Management sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 529,839 shares — an estimated $5.49M sold.

TCG Crossover Management first reported a position in ACRS in Q4 2021 and held it in 7 quarters. The position peaked at $19.7M in Q1 2022. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

  • TCG Crossover Management reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • TCG Crossover Management sold 529,839 Aclaris Therapeutics shares in Q3 2023, an estimated $5.49M.
  • TCG Crossover Management first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 7 quarters.
  • TCG Crossover Management's Aclaris Therapeutics position peaked at $19.7M in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on TCG Crossover Management's 13F filing for Q3 2023, filed 14 Nov 2023.